Novavax (NVAX) Reports RSV F Vaccine Phase 3 Missed Primary, Secondary Efficacy Objectives
- Stocks close with gains, led by Dow as investors look for rate insight
- Piper Sandler: Stock rally likely to continue on rising recession risks
- Robinhood (HOOD) rises after saying it plans to launch a credit card for US consumers
- Short sellers target Reddit shares as stock slips
- RH touts 'exceptional' demand for new collections after Q4 results fall short
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults
September 15, 2016 4:18 PM EDTTopline data from the Resolve Phase 3 trial did not meet pre-specified efficacy objectives The attack rate for the Phase 3 primary objective was approximately 25% of that observed in Phase 2 trial Topline data from our Phase 2 rollover trial suggest improved vaccine efficacy from a second year of dosing
Management will host a conference call at 5:00 pm ET time today
GAITHERSBURG, Md., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) today announced topline data from two clinical... More